clinical outcome assessment of parkinson's disease patients treated with xadago (safinamide)

Conditions: Idiopathic Parkinson Disease

Summary: this is a phase iv, prospective, observational, post-marketing study designed to obtain additional data on the effect of xadago on motor and non-motor symptoms in parkinson's disease patients newly prescribed xadago.

this phase iv, multicenter, prospective, observational study to evaluate clinician-reported outcomes and patient-reported outcomes related to motor and non-motor symptoms, health status, quality of life and treatment satisfaction in pd patients who have been newly prescribed xadago according to package insert indication. this study also will gather "real world" data from a pd population in the us regarding their overall experience and degree of satisfaction with the use of xadago as an add-on treatment to their l-dopa regimen. treatment experience will be captured using patient self-rating assessments as well as clinician ratings on assessments.

Eligibility criteria:
inclusion criteria: 1. patient (and care partner, if required per inclusion criterion 6) is able to understand and provide signed informed consent and hipaa authorization in english. 2. patient with diagnosis of idiopathic pd (all stages). 3. independent of the study, clinician's and patient's choice of treatment is xadago in accordance with the package insert indication. 4. patient is willing and able to participate in the study and complete study-related assessments for 2 months and, patients can continue for an optional 4-month study extension. 5. patient has access to an electronic device for the interim completion of pros. 6. patient has an available care partner who is able and willing to assist with clinic attendance and completion of study assessments (e.g., pros, health outcomes, etc.), if in the pi's opinion, assistance is needed to comply with all study visits and procedures. exclusion criteria: 1. any of the warnings, precautions, or contraindications listed in the xadago package insert that in the opinion of the pi would prevent appropriate treatment with xadago or impair study participation (e.g., pregnancy, lactation, severe hepatic impairment, etc.). 2. participation in any other clinical trial of an investigational drug or device within 4 weeks prior to the baseline visit or at any time during the study. 3. patient is currently receiving chemotherapy or radiation for any form of cancer (if history of cancer, must be in clinical remission at study entry) or currently receiving immunotherapy. 4. patients with conditions that are likely to prevent them from accurately and reliably completing study assessments, including evidence of moderate or severe dementia as determined by the clinician (not to include mild cognitive impairment \[mci\]); major psychiatric illness (specifically diagnosis of schizophrenia, bipolar disorder or a history of attempted suicide); and/or severe and progressive medical illness (including terminal cancer, end-stage renal disease +/- undergoing dialysis). 5. severe or unpredictable dyskinesia at the time of the baseline visit. 6. previous participation in this study; a patient may not re-enroll after prior discontinuation or completion

Keywords: parkinson's disease safinamide xadago mao-b inhibitor off non-motor symptoms motor symptoms levodopa pd